At a glance
ClinicalIndex Comparison RecordPhase 2Completed· 226 enrolled
Drug / intervention
CBP-201 +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Randomized, Double-Blind, Placebo-Controlled Multi-Centered Study of the Efficacy, Safety, Pharmacokinetics and Pharmacodynamics of CBP-201 in Adult Subjects With Moderate to Severe Atopic Dermatitis
In Brief
A Phase 2 clinical trial evaluating CBP-201 and placebo for Moderate-to-severe Atopic Dermatitis. Completed, enrolled 226 participants across 59 sites in 4 countries.
Detailed Summary
This study will evaluate the efficacy, safety, pharmacokinetics and pharmacodynamics of CBP-201 in adult subjects with moderate to severe atopic dermatitis.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsModerate-to-severe Atopic Dermatitis
CountriesAustralia, China, New Zealand, United States
Collaborators--
Timeline
Phase 2CompletedFinished
202120222023202420252026
First PostedJun 2020
Enrollment StartJul 2020
Primary CompletionJul 2021
Study CompletionSep 2021
TodayJul 2026
First PostedJun 24, 2020
Enrollment StartJul 17, 2020
Primary CompletionJul 28, 2021
Study CompletionSep 22, 2021
TodayJul 2, 2026
Enrollment to primary: 1.0 yearsPosted 6.0 years ago
Interventions
CBP-201drug
CBP-201 subcutaneous(SC) injection.
placebodrug
subcutaneous(SC) injection